Capstone Therapeutics (CAPS) Competitors $1.24 -0.05 (-3.88%) As of 08/15/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock CAPS vs. ZVSA, SRNE, PBLA, HEPA, BPTSY, VIRX, TRVN, MYMD, BON, and VINCShould you be buying Capstone Therapeutics stock or one of its competitors? The main competitors of Capstone Therapeutics include ZyVersa Therapeutics (ZVSA), Sorrento Therapeutics (SRNE), Panbela Therapeutics (PBLA), Hepion Pharmaceuticals (HEPA), Biophytis (BPTSY), Viracta Therapeutics (VIRX), Trevena (TRVN), MyMD Pharmaceuticals (MYMD), Bon Natural Life (BON), and Vincerx Pharma (VINC). These companies are all part of the "pharmaceutical products" industry. Capstone Therapeutics vs. Its Competitors ZyVersa Therapeutics Sorrento Therapeutics Panbela Therapeutics Hepion Pharmaceuticals Biophytis Viracta Therapeutics Trevena MyMD Pharmaceuticals Bon Natural Life Vincerx Pharma Capstone Therapeutics (NASDAQ:CAPS) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk. Which has preferable earnings and valuation, CAPS or ZVSA? Capstone Therapeutics has higher revenue and earnings than ZyVersa Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCapstone Therapeutics$44.88M0.00-$2.56MN/AN/AZyVersa TherapeuticsN/AN/A-$9.41MN/AN/A Is CAPS or ZVSA more profitable? Capstone Therapeutics' return on equity of 0.00% beat ZyVersa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Capstone TherapeuticsN/A N/A N/A ZyVersa Therapeutics N/A -109.54%-43.95% Do insiders and institutionals believe in CAPS or ZVSA? 2.6% of Capstone Therapeutics shares are held by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are held by institutional investors. 42.8% of Capstone Therapeutics shares are held by insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, CAPS or ZVSA? Capstone Therapeutics has a beta of -0.8, meaning that its share price is 180% less volatile than the S&P 500. Comparatively, ZyVersa Therapeutics has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Does the media refer more to CAPS or ZVSA? In the previous week, ZyVersa Therapeutics had 3 more articles in the media than Capstone Therapeutics. MarketBeat recorded 5 mentions for ZyVersa Therapeutics and 2 mentions for Capstone Therapeutics. Capstone Therapeutics' average media sentiment score of 0.81 beat ZyVersa Therapeutics' score of 0.00 indicating that Capstone Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Capstone Therapeutics Positive ZyVersa Therapeutics Neutral SummaryCapstone Therapeutics beats ZyVersa Therapeutics on 6 of the 9 factors compared between the two stocks. Get Capstone Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CAPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CAPS vs. The Competition Export to ExcelMetricCapstone TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$200K$3.14B$5.72B$9.79BDividend YieldN/A2.22%3.91%4.13%P/E RatioN/A21.0331.1425.06Price / Sales0.00285.40416.7890.80Price / CashN/A42.6136.7858.67Price / Book-0.068.659.086.18Net Income-$2.56M-$54.65M$3.26B$265.11M7 Day Performance-6.06%6.56%7.39%4.22%1 Month Performance-23.46%4.82%4.22%0.77%1 Year PerformanceN/A15.81%30.30%24.69% Capstone Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CAPSCapstone TherapeuticsN/A$1.24-3.9%N/AN/A$200K$44.88M0.0038News CoverageEarnings ReportHigh Trading VolumeZVSAZyVersa Therapeutics0.7142 of 5 stars$0.17-0.1%N/A-94.5%$828KN/A0.002News CoverageGap DownSRNESorrento Therapeutics0.6726 of 5 stars$0.00-34.8%N/A-76.7%$827K$60.32M0.00800Gap DownPBLAPanbela Therapeutics1.1245 of 5 stars$0.16flatN/A-57.2%$767KN/A0.006Short Interest ↓HEPAHepion Pharmaceuticals0.922 of 5 stars$0.06+10.9%N/A-99.8%$733KN/A-0.0120News CoverageShort Interest ↓Gap UpBPTSYBiophytisN/A$1.81flatN/A-67.2%$634KN/A0.0030Short Interest ↓VIRXViracta Therapeutics1.7566 of 5 stars$0.01flat$1.75+17,793.7%N/A$389KN/A-0.0120News CoverageTRVNTrevena1.1516 of 5 stars$0.25flat$5.00+1,900.0%N/A$240K$443K-0.0140Short Interest ↑MYMDMyMD PharmaceuticalsN/A$0.10-1.6%N/A-94.4%$229KN/A0.006High Trading VolumeBONBon Natural LifeN/A$1.31+2.3%N/AN/A$220K$23.84M0.00100VINCVincerx Pharma2.7285 of 5 stars$0.04-18.8%$40.00+100,402.5%-99.7%$208KN/A0.0060 Related Companies and Tools Related Companies ZVSA Alternatives SRNE Alternatives PBLA Alternatives HEPA Alternatives BPTSY Alternatives VIRX Alternatives TRVN Alternatives MYMD Alternatives BON Alternatives VINC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CAPS) was last updated on 8/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capstone Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capstone Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access